Abstract 1727P
Background
Oncology databases/cancer registries can help facilitate quality cancer care and novel research. Their maintenance remains challenging in low and middle-income countries (LMICs). We explored barriers and facilitators of oncology database maintenance in Ukraine.
Methods
We conducted semi-structured interviews with a purposeful sample of oncology physicians at the Ukraine National Cancer Institute (NCI) to explore barriers and facilitators of oncology database data entry and use. Interviews were audio-recorded, transcribed, and analyzed via hybrid analysis.
Results
13 physicians were interviewed, including 6 (46%) junior and 7 (54%) senior NCI faculty. All were aware of local or international oncology databases. 10 (77%) entered patient data into them, including 7 (54%) to international and 8 (62%) to local databases. 6 (69%) thought that most of their oncology colleagues in Ukraine are not aware of the existence or value of cancer databases. The following themes have been identified: perceived benefits of cancer databases included improving patient care, research, standardizing clinical practice, care monitoring, and quality improvement. Obstacles of data entry included: time required, low quality of medical documentation, complex online interface. Some thought that physicians should be responsible for data entry, while others thought it should be done by nonmedical providers. Facilitators of data entry included appointing a physician leader to oversee quality and engagement, direct direction from supervisor, use for research publication or as part of a project of personal interest, monetary compensation, collaborating with colleagues abroad, data entry training.
Conclusions
Factors affecting data entry into and use of local and international cancer databases by oncology physicians in Ukraine included perceived benefits for career and patient care, required time, requirements from leadership, database technology characteristics. Given limited resources for local and population-based cancer registry maintenance in Ukraine and other LMICs, novel low-cost strategies for this are urgently needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1912TiP - STELLAR-304: A randomized phase III study of zanzalintinib (XL092) and nivolumab in non-clear cell renal cell carcinoma (nccRCC)
Presenter: Sumanta Pal
Session: Poster session 23
2366P - Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer (NICARAGUA trial)
Presenter: Daniel Castellano Gauna
Session: Poster session 23
2367P - A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Russells Pachynski
Session: Poster session 23
2368P - Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
Presenter: Patrizia Giannatempo
Session: Poster session 23
2369P - Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
Presenter: Bradley McGregor
Session: Poster session 23
2370P - Updated results of PEANUT trial: Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma (mUC)
Presenter: Achille Bottiglieri
Session: Poster session 23
2371P - Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from the JAVELIN Bladder 100 trial in older patients (pts)
Presenter: Shilpa Gupta
Session: Poster session 23
2372P - Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
Presenter: Marc-Oliver Grimm
Session: Poster session 23
2373P - Outcomes by retrospective eligibility for maintenance therapy of patients (pts) with advanced urothelial carcinoma (UC): Post hoc analysis of KEYNOTE-361
Presenter: Ronac Mamtani
Session: Poster session 23
2374P - A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
Presenter: Petros Grivas
Session: Poster session 23